Go Pro
→ The $15 Gold Fund That Pays Up to $1,152/Month (From Investors Alley) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cadrenal Therapeutics, Inc. stock logo
CVKD
Cadrenal Therapeutics
$1.87
+0.5%		$2.71
$1.76
▼
$14.64
$6.35M1.8445,595 shs27,905 shs
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
$0.40
+14.7%		$0.30
$0.23
▼
$2.75
$5.35M0.8442.10 million shs18.47 million shs
Orgenesis Inc. stock logo
ORGS
Orgenesis
$0.35
+0.0%		$0.33
$0.00
▼
$1.00
$1.81M3.22971 shs100 shs
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
$1.30
-3.0%		$1.19
$0.85
▼
$5.60
$6.42M1.28213,598 shs189,730 shs
10 Stocks Powering The Next AI Boom Cover
10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cadrenal Therapeutics, Inc. stock logo
CVKD
Cadrenal Therapeutics
+0.54%-4.10%-20.43%-62.97%-83.99%
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
+14.75%-23.13%+37.23%+42.77%-81.40%
Orgenesis Inc. stock logo
ORGS
Orgenesis
+0.03%0.00%+1,742.11%+11,566.67%+1,490.91%
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
-2.99%-9.72%+6.56%+19.27%-57.52%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cadrenal Therapeutics, Inc. stock logo
CVKD
Cadrenal Therapeutics
$1.87
+0.5%		$2.71
$1.76
▼
$14.64
$6.35M1.8445,595 shs27,905 shs
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
$0.40
+14.7%		$0.30
$0.23
▼
$2.75
$5.35M0.8442.10 million shs18.47 million shs
Orgenesis Inc. stock logo
ORGS
Orgenesis
$0.35
+0.0%		$0.33
$0.00
▼
$1.00
$1.81M3.22971 shs100 shs
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
$1.30
-3.0%		$1.19
$0.85
▼
$5.60
$6.42M1.28213,598 shs189,730 shs
10 Stocks Powering The Next AI Boom Cover
10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cadrenal Therapeutics, Inc. stock logo
CVKD
Cadrenal Therapeutics
+0.54%-4.10%-20.43%-62.97%-83.99%
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
+14.75%-23.13%+37.23%+42.77%-81.40%
Orgenesis Inc. stock logo
ORGS
Orgenesis
+0.03%0.00%+1,742.11%+11,566.67%+1,490.91%
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
-2.99%-9.72%+6.56%+19.27%-57.52%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Cadrenal Therapeutics, Inc. stock logo
CVKD
Cadrenal Therapeutics
2.00
Hold$13.00595.19% Upside
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
1.00
SellN/AN/A
Orgenesis Inc. stock logo
ORGS
Orgenesis
0.00
N/AN/AN/A
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
1.00
SellN/AN/A

Current Analyst Ratings Breakdown

Latest ORGS, CVKD, SNOA, and ENSC Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/7/2026
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
7/24/2026
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
7/17/2026
Cadrenal Therapeutics, Inc. stock logo
CVKD
Cadrenal Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
7/17/2026
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
(Data available from 8/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Cadrenal Therapeutics, Inc. stock logo
CVKD
Cadrenal Therapeutics
N/AN/AN/AN/A$1.17 per shareN/A
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
$5.07M1.21N/AN/A$0.63 per share0.63
Orgenesis Inc. stock logo
ORGS
Orgenesis
$662K2.73N/AN/A($6.58) per share-0.05
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
$19.53M0.32N/AN/A$1.38 per share0.94
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Cadrenal Therapeutics, Inc. stock logo
CVKD
Cadrenal Therapeutics
-$13.24M-$5.63N/AN/AN/AN/A-476.34%-307.13%N/A
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
-$10.18M-$3.35N/AN/AN/A-280.53%-1,225.23%-295.90%N/A
Orgenesis Inc. stock logo
ORGS
Orgenesis
-$55.36M-$11.51N/AN/AN/A-3,827.81%N/A-130.18%N/A
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
-$3.17M-$1.22N/AN/AN/A-10.33%-21.41%-6.08%N/A

Latest ORGS, CVKD, SNOA, and ENSC Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/13/2026Q2 2026
Cadrenal Therapeutics, Inc. stock logo
CVKD
Cadrenal Therapeutics
-$1.42-$1.14+$0.28-$1.14N/AN/A
8/13/2026Q2 2026
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
-$0.50-$0.20+$0.30-$0.20$1.20 million$1.16 million
8/6/2026Q1 2027
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
-$0.30$0.02+$0.32-$0.09$4.99 million$6.41 million
6/16/2026Q4 2026
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
-$0.24-$0.33-$0.09-$0.33$5.57 million$5.56 million
5/15/2026Q1 2026
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
-$0.73-$0.52+$0.21-$0.52$1.00 million$0.96 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Cadrenal Therapeutics, Inc. stock logo
CVKD
Cadrenal Therapeutics
N/AN/AN/AN/AN/A
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
N/AN/AN/AN/AN/A
Orgenesis Inc. stock logo
ORGS
Orgenesis
N/AN/AN/AN/AN/A
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Cadrenal Therapeutics, Inc. stock logo
CVKD
Cadrenal Therapeutics
N/A
2.68
2.68
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
N/A
0.71
0.71
Orgenesis Inc. stock logo
ORGS
Orgenesis
N/A
0.07
0.07
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
N/A
2.99
1.75

Institutional Ownership

CompanyInstitutional Ownership
Cadrenal Therapeutics, Inc. stock logo
CVKD
Cadrenal Therapeutics
7.92%
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
5.63%
Orgenesis Inc. stock logo
ORGS
Orgenesis
22.56%
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
1.95%

Insider Ownership

CompanyInsider Ownership
Cadrenal Therapeutics, Inc. stock logo
CVKD
Cadrenal Therapeutics
14.59%
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
2.80%
Orgenesis Inc. stock logo
ORGS
Orgenesis
1.91%
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
1.02%
CompanyEmployeesShares OutstandingFree FloatOptionable
Cadrenal Therapeutics, Inc. stock logo
CVKD
Cadrenal Therapeutics
43.42 million2.92 millionNot Optionable
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
1015.37 million14.94 millionNot Optionable
Orgenesis Inc. stock logo
ORGS
Orgenesis
1505.17 million4.53 millionNo Data
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
1804.79 million4.74 millionNot Optionable

Recent News About These Companies

Sonoma Pharmaceuticals Delivers 141% U.S. Revenue Growth in FY Q1, 60% Total Revenue Growth and First-Ever Positive Adjusted EBITDA
August 6, 2026  |  accessnewswire.comA
Sonoma Pharmaceuticals Turns EBITDA Positive for First Time with Record Quarterly Revenue
August 6, 2026  |  benzinga.comhttps://www.benzinga.com/markets/earnings/26/08/60993290/sonoma-pharmaceuticals-turns-ebitda-positive-for-first-time-with-record-quarterly-revenue?utm_source=snapi
Sonoma Pharmaceuticals Receives FDA 510(k) Clearance Expanding Indications and Packaging Options for Microdacyn(R) Wound Irrigation Solution
June 30, 2026  |  accessnewswire.comA
Sonoma Pharmaceuticals Expands At-the-Market Equity Offering Capacity
June 18, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/sonoma-pharmaceuticals-expands-at-the-market-equity-offering-capacity?utm_source=marketbeat.com&utm_medium=referral
Sonoma Pharmaceuticals, Inc.: Sonoma Pharmaceuticals Reports Fiscal Year and Fourth Quarter 2026 Financial Results
June 16, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-06/68784561-sonoma-pharmaceuticals-inc-sonoma-pharmaceuticals-reports-fiscal-year-and-fourth-quarter-2026-financial-results-200.htm
Sonoma Pharmaceuticals Reports Fiscal Year and Fourth Quarter 2026 Financial Results
June 16, 2026  |  accessnewswire.comA
What's going on with Sonoma Pharma stock Monday?
April 27, 2026  |  msn.comhttps://www.msn.com/en-us/money/top-stocks/what-s-going-on-with-sonoma-pharma-stock-monday/ar-AA21PdPx
Sonoma Pharmaceuticals Announces Pricing of $4 Million Public Offering
April 25, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/sectors/healthcare/articles/sonoma-pharmaceuticals-announces-pricing-4-132100121.html
Sonoma Pharmaceuticals, Inc.: Sonoma Pharmaceuticals Announces U.S. Retail Launch of Advanced Burn Relief Hydrogel in CVS and Walmart
March 24, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-03/68022819-sonoma-pharmaceuticals-inc-sonoma-pharmaceuticals-announces-u-s-retail-launch-of-advanced-burn-relief-hydrogel-in-cvs-and-walmart-200.htm
Sonoma Pharmaceuticals Announces U.S. Retail Launch of Advanced Burn Relief Hydrogel in CVS and Walmart
March 24, 2026  |  accessnewswire.comA
Sonoma Pharmaceuticals Announces Launch of New Dermatology Product Line under Person & Covey’s Aquanil Brand for Sensitive Skin
March 18, 2026  |  freep.comF
Sonoma Pharmaceuticals Announces Launch of New Dermatology Product Line under Person & Covey's Aquanil Brand for Sensitive Skin
March 18, 2026  |  accessnewswire.comA
Sonoma Pharmaceuticals, Inc.: Sonoma Pharmaceuticals Reports Third Fiscal Quarter 2026 Financial Results
February 10, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-02/67666437-sonoma-pharmaceuticals-inc-sonoma-pharmaceuticals-reports-third-fiscal-quarter-2026-financial-results-200.htm
Sonoma Pharmaceuticals Reports Third Fiscal Quarter 2026 Financial Results
February 10, 2026  |  accessnewswire.comA
Sonoma Pharmaceuticals, Inc.: Sonoma Pharmaceuticals Welcomes New Member of its Board of Directors and New Senior Vice President of Regulatory, Quality and Product Development
January 29, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-01/67552599-sonoma-pharmaceuticals-inc-sonoma-pharmaceuticals-welcomes-new-member-of-its-board-of-directors-and-new-senior-vice-president-of-regulatory-qualit-200.htm
Sonoma Pharmaceuticals Welcomes New Member of its Board of Directors and New Senior Vice President of Regulatory, Quality and Product Development
January 28, 2026  |  accessnewswire.comA
Sonoma Pharmaceuticals, Inc.: National Rosacea Society Awards Seal of Acceptance to Sonoma Pharmaceuticals for Reliefacyn Advanced
November 14, 2025  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2025-11/66971748-sonoma-pharmaceuticals-inc-national-rosacea-society-awards-seal-of-acceptance-to-sonoma-pharmaceuticals-for-reliefacyn-advanced-200.htm
Sonoma Pharmaceuticals’ Reliefacyn Advanced receives NRS Seal of Acceptance
November 13, 2025  |  msn.comhttps://www.msn.com/en-us/health/diseases-and-conditions/sonoma-pharmaceuticals-reliefacyn-advanced-receives-nrs-seal-of-acceptance/ar-AA1QnZQ4
National Rosacea Society Awards Seal of Acceptance to Sonoma Pharmaceuticals for Reliefacyn Advanced
November 13, 2025  |  accessnewswire.comA
Sonoma Pharmaceuticals reports higher revenue
November 7, 2025  |  bizwest.comB

New MarketBeat Followers Over Time

Media Sentiment Over Time

Cadrenal Therapeutics stock logo

Cadrenal Therapeutics NASDAQ:CVKD

$1.87 +0.01 (+0.54%)
Closing price 08/14/2026 04:00 PM Eastern
Extended Trading
$1.84 -0.03 (-1.34%)
As of 08/14/2026 07:47 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. Cadrenal Therapeutics, Inc. was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.

Ensysce Biosciences stock logo

Ensysce Biosciences NASDAQ:ENSC

$0.40 +0.05 (+14.75%)
Closing price 08/14/2026 04:00 PM Eastern
Extended Trading
$0.36 -0.04 (-8.98%)
As of 08/14/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology. The company is developing PF614, a TAAP oxycodone prodrug candidate for the treatment of acute or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat for overdose protection against excessive oral ingestion, as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. It is also developing PF614, an extended-release oxycodone-derivative that releases clinically effective oxycodone; PF329 for pain with abuse protection; PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD; and PF9001 to treat Opioid use disorder. The company was founded in 2003 and is based in La Jolla, California.

Orgenesis stock logo

Orgenesis NASDAQ:ORGS

$0.35 +0.00 (+0.03%)
As of 08/14/2026 09:58 AM Eastern

Orgenesis Inc., a biotech company, focuses on cell and gene therapies worldwide. It operates through two segments, Octomera and Therapies. The company develops a Point of Care (POCare) platform that includes a pipeline of licensed cell based POCare therapies that are processed and produced under closed and automated POCare technology systems across a collaborative POCare network consisting of research institutes and hospitals. Its therapies include autologous; cell-based immunotherapies; and therapeutics for metabolic diseases, anti-viral diseases, and tissue regeneration. The company also provides development services, including regulatory services, pre-clinical studies, intellectual property services, and GMP process translation, as well as support services; hospital services; cell process development services; and distributed cell processing services. The company was formerly known as Business Outsourcing Service, Inc. and changed its name to Orgenesis Inc. in August 2011. Orgenesis Inc. was incorporated in 2008 and is headquartered in Germantown, Maryland.

Sonoma Pharmaceuticals stock logo

Sonoma Pharmaceuticals NASDAQ:SNOA

$1.30 -0.04 (-2.99%)
Closing price 08/14/2026 04:00 PM Eastern
Extended Trading
$1.31 +0.01 (+0.77%)
As of 08/14/2026 07:45 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Sonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, Asia, and internationally. The company offers Regenacyn, a prescription scar gel; Pediacyn, a pediatric dermatology and wound care product for over-the-counter (OTC) use; Epicyn, an Antimicrobial Facial Cleanser; Levicyn, an HOCl based prescription and OTC product to use and relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; and SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis. It also provides Gramaderm for the treatment of topical mild to moderate acne; Microcyn, a HOCl-based topical line of products designed to stimulate expedited healing by targeting a wide range of pathogens; Ocucyn eyelid and eyelash cleanser; Microdacyn60 oral care solution for the treatment of mouth and throat infections; and Podiacyn, a foot care product. In addition, the company offers MicrocynAH, an HOCl-based solution designed to relieve common symptoms of hot spots, scratches, skin rashes post-surgical sites, and irritated animal skin for healing; MicrocynVS, a veterinarian-strength animal care product used in vet clinics and animal hospitals; Nanocyn, a hospital-grade disinfectant; Acuicyn, an antimicrobial prescription solution for the treatment of blepharitis and the daily hygiene of eyelids and lashes; MucoClyns for the use in emergencies and safe to use on mucous membranes, cuts, abrasions, burns, and body surfaces; Endocyn root canal irrigation solutions; and Sinudox for nasal irrigation. The company was formerly known as Oculus Innovative Sciences, Inc. and changed its name to Sonoma Pharmaceuticals, Inc. in December 2016. Sonoma Pharmaceuticals, Inc. was incorporated in 1999 and is based in Boulder, Colorado.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas